---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-051737"
form_type: "8-K"
ticker: "NUWE"
cik: "0001506492"
company_name: "Nuwellis, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T14:46:57.908662+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nuwellis Q3 revenue up 17% YoY to $2.4M; net loss narrows to $3.4M

## Summary
- Revenue of $2.4M (+17% YoY); circuit sales driving growth with 26% increase in therapy utilization.
- Gross margin 57.3% vs 61.0% YoY due to lower console volumes; disposable margins at 74.0%.
- Net loss $3.4M ($1.81 loss per share) vs $3.9M ($36.72) YoY; lower expenses and higher share count.
- Cash $4.9M, no debt; closed $2.25M public offering on Oct 17 for additional capital.
- Collaborations with SeaStar (pediatric SCD device distribution) and DaVita (pilot phase) progressing.

## SEC filing metadata
- accession: 0001140361-23-051737
- form_type: 8-K
- ticker: NUWE
- cik: 0001506492
- company_name: Nuwellis, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506492/000114036123051737/0001140361-23-051737-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506492/000114036123051737/ef20014069_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-051737
- JSON: https://secwatch.observer/filing/0001140361-23-051737.json
- Plain text: https://secwatch.observer/filing/0001140361-23-051737.txt

## Key facts
- Earnings Releases
  Nuwellis, Inc. reported the third quarter ended September 30, 2023 results: revenue $2.4 million, net income $3.4 million, EPS a loss of $1.81 per share.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $2.4 million
  - Net income: $3.4 million
  - EPS: a loss of $1.81 per share
  - Result: reported results
  source text: company dedicated to transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2023. • Revenue of $2.4 million for the third quarter 2023, increased 16% over the prior quarter and increased 17% over the prior-year period. • Therapy utilization, or the number of circuits per placed
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506492/000114036123051737/0001140361-23-051737-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.